The summaries are free for public
use. The Chronic Liver Disease
Foundation will continue to add and
archive summaries of articles deemed
relevant to CLDF by the Board of
Trustees and its Advisors.
Abstract Details
Liver Transplantation for NAFLD: indications and post-transplant management
Clin Mol Hepatol. 2022 Dec 28. doi: 10.3350/cmh.2022.0392. Online ahead of print.
1Gastroenterology and Multivisceral Transplant Unit, Department of Surgery, Oncology and Gastroenterology. Padua University Hospital. University of Padua. Padua, Italy.
Abstract
Non-alcoholic fatty liver disease (NAFLD) is currently the fastest growing indication to liver transplantation (LT) in Western Counties, both for end stage liver disease (ESLD) and hepatocellular carcinoma (HCC). NAFLD/NASH is often expression of a systemic metabolic syndrome; therefore, NAFLD/NASH patients require a multidisciplinary approach for a proper pre-surgical evaluation, which is important to achieve a post-transplant outcome comparable to that of other indications to LT. NAFLD/NASH patients are also at higher risk of post-transplant cardiovascular (CV) events, diabetes, dyslipidemia, obesity, renal impairment and recurrent NASH. Lifestyle modifications, included diet and physical activity, are key to improve survival and quality of life after transplantation. A tailored immunosuppressive regimen may be proposed in selected patients. Development of new drugs for the treatment of recurrent NASH is awaited.